Published in Cancer Biol Ther on March 01, 2012
Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res (2012) 1.20
The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair. Mol Cancer Ther (2013) 0.91
Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia. Leukemia (2013) 0.82
DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance. Chromosoma (2014) 0.81
PLK1 is a binding partner and a negative regulator of FOXO3 tumor suppressor. Discoveries (Craiova) (2015) 0.76
The cell cycle checkpoint inhibitors in the treatment of leukemias. J Hematol Oncol (2017) 0.75
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. Leuk Res (2017) 0.75
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature (2005) 18.30
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature (2005) 14.65
An oncogene-induced DNA damage model for cancer development. Science (2008) 11.60
DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol (2007) 5.78
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther (2008) 3.07
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med (2010) 2.44
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res (2010) 2.34
Antileukemic activity of rapamycin in acute myeloid leukemia. Blood (2004) 2.03
Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia (2008) 1.70
Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene (2004) 1.58
In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res (2010) 1.48
Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival. Mol Pharmacol (2009) 1.33
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood (2005) 1.23
Claspin and Chk1 regulate replication fork stability by different mechanisms. Cell Cycle (2009) 1.21
Targeting DNA checkpoint kinases in cancer therapy. Cancer Biol Ther (2003) 1.17
Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia (2003) 1.08
Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy. Cancer Res (2009) 1.03
High-throughput assay for G2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide. Cancer Res (1998) 0.96
G2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress. Oncogene (2008) 0.94
Chk1 haploinsufficiency results in anemia and defective erythropoiesis. PLoS One (2010) 0.89
Complex karyotypes confer a poor survival in adult acute myeloid leukemia with unfavorable cytogenetic abnormalities. Cancer Genet Cytogenet (2007) 0.80
Identification of N-terminally truncated stable nuclear isoforms of CDC25B that are specifically involved in G2/M checkpoint recovery. Cancer Res (2011) 0.79
A new mitotic-cell specific monoclonal antibody. Cell Cycle (2007) 0.78
CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer (2007) 3.46
The human dynamin-related protein OPA1 is anchored to the mitochondrial inner membrane facing the inter-membrane space. FEBS Lett (2002) 2.30
The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol (2006) 2.28
Antileukemic activity of rapamycin in acute myeloid leukemia. Blood (2004) 2.03
The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol (2015) 1.98
Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2-M transition. J Cell Sci (2004) 1.93
53BP1 exchanges slowly at the sites of DNA damage and appears to require RNA for its association with chromatin. J Cell Sci (2005) 1.62
Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status. Leuk Res (2009) 1.52
DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability. Proc Natl Acad Sci U S A (2010) 1.48
Pharmacological inhibition of aurora-A but not aurora-B impairs interphase microtubule dynamics. Cell Cycle (2009) 1.48
The cell cycle regulator CDC25A is a target for JAK2V617F oncogene. Blood (2011) 1.47
3D imaging of the response to CDC25 inhibition in multicellular spheroids. Cancer Biol Ther (2009) 1.45
Microcephalin and pericentrin regulate mitotic entry via centrosome-associated Chk1. J Cell Biol (2009) 1.41
A critical role for Lyn in acute myeloid leukemia. Blood (2007) 1.40
SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias. Leuk Lymphoma (2012) 1.39
Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res (2004) 1.38
Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood (2009) 1.31
Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancer. BMC Cancer (2012) 1.28
The AT-hook protein D1 is essential for Drosophila melanogaster development and is implicated in position-effect variegation. Mol Cell Biol (2002) 1.26
Cell cycle control by the CDC25 phosphatases. Anticancer Agents Med Chem (2008) 1.22
OPA1 functions in mitochondria and dysfunctions in optic nerve. Int J Biochem Cell Biol (2009) 1.19
mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle (2005) 1.19
CDC25B phosphorylation by Aurora-A occurs at the G2/M transition and is inhibited by DNA damage. Cell Cycle (2005) 1.18
CHK1 phosphorylates CDC25B during the cell cycle in the absence of DNA damage. J Cell Sci (2006) 1.16
The chromatin remodeler p400 ATPase facilitates Rad51-mediated repair of DNA double-strand breaks. J Cell Biol (2012) 1.15
Molecular and functional characterization of SLC26A11, a sodium-independent sulfate transporter from high endothelial venules. FASEB J (2003) 1.13
Live cell division dynamics monitoring in 3D large spheroid tumor models using light sheet microscopy. Cell Div (2011) 1.12
Human pEg3 kinase associates with and phosphorylates CDC25B phosphatase: a potential role for pEg3 in cell cycle regulation. Oncogene (2002) 1.11
High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica (2011) 1.07
CDC25B involvement in the centrosome duplication cycle and in microtubule nucleation. Cancer Res (2007) 1.06
Tumor necrosis factor-alpha inhibits hTERT gene expression in human myeloid normal and leukemic cells. Blood (2005) 1.05
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood (2013) 1.04
Clinicopathologic features of graft rejection of the first human hand allograft. Transplantation (2003) 1.04
Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy. Cancer Res (2009) 1.03
Design, synthesis, and biological evaluation of novel naphthoquinone derivatives with CDC25 phosphatase inhibitory activity. Bioorg Med Chem (2005) 1.03
Tumor necrosis factor alpha induces senescence and chromosomal instability in human leukemic cells. Oncogene (2004) 1.02
Interaction of p21(CDKN1A) with PCNA regulates the histone acetyltransferase activity of p300 in nucleotide excision repair. Nucleic Acids Res (2008) 1.01
Protein kinase CK2 regulates CDC25B phosphatase activity. Oncogene (2003) 1.00
MAP kinase-dependent degradation of p27Kip1 by calpains in choroidal melanoma cells. Requirement of p27Kip1 nuclear export. J Biol Chem (2003) 0.99
Genotoxic-activated G2-M checkpoint exit is dependent on CDC25B phosphatase expression. Mol Cancer Ther (2006) 0.99
The polo-like kinase 1 regulates CDC25B-dependent mitosis entry. Biochim Biophys Acta (2009) 0.98
TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine (2011) 0.96
Multicellular tumor spheroid models to explore cell cycle checkpoints in 3D. BMC Cancer (2013) 0.95
Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood (2013) 0.94
Receptor-based virtual ligand screening for the identification of novel CDC25 phosphatase inhibitors. J Chem Inf Model (2007) 0.94
Emerging roles of phosphatidylinositol monophosphates in cellular signaling and trafficking. Adv Enzyme Regul (2005) 0.94
What's new on CDC25 phosphatase inhibitors. Pharmacol Ther (2007) 0.94
CDC25B phosphorylated by pEg3 localizes to the centrosome and the spindle poles at mitosis. Cell Cycle (2005) 0.94
p21CDKN1A does not interfere with loading of PCNA at DNA replication sites, but inhibits subsequent binding of DNA polymerase delta at the G1/S phase transition. Cell Cycle (2003) 0.93
Characterization of the antiproliferative activity of Xylopia aethiopica. Cell Div (2012) 0.92
Myristoylated alanine-rich C kinase substrate (MARCKS) is involved in myoblast fusion through its regulation by protein kinase Calpha and calpain proteolytic cleavage. Biochem J (2004) 0.92
Moderate variations in CDC25B protein levels modulate the response to DNA damaging agents. Cell Cycle (2008) 0.92
Deep and clear optical imaging of thick inhomogeneous samples. PLoS One (2012) 0.91
CDC25B phosphorylation by p38 and MK-2. Cell Cycle (2006) 0.91
CDC25A: a rebel within the CDC25 phosphatases family? Anticancer Agents Med Chem (2008) 0.90
Identification of an unexpected link between the Shh pathway and a G2/M regulator, the phosphatase CDC25B. Dev Biol (2006) 0.90
A functional link between polo-like kinase 1 and the mammalian target-of-rapamycin pathway? Cell Cycle (2010) 0.90
Distinct pools of proliferating cell nuclear antigen associated to DNA replication sites interact with the p125 subunit of DNA polymerase delta or DNA ligase I. Exp Cell Res (2004) 0.90
Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases. Mol Cancer Ther (2005) 0.89
Opioid receptor blockade reduces Fas-induced hepatitis in mice. Hepatology (2004) 0.89
Linking PCNA-dependent replication and ATR by human Claspin. Biochem Biophys Res Commun (2007) 0.88
Hemophagocytic syndrome in patients with acute myeloid leukemia undergoing intensive chemotherapy. Haematologica (2013) 0.88
IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells. Int J Cancer (2009) 0.88
Acrodermatitis continua of Hallopeau treated successfully with ustekinumab and acitretin after failure of tumour necrosis factor blockade and anakinra. Dermatology (2014) 0.88
Mechanical stress impairs mitosis progression in multi-cellular tumor spheroids. PLoS One (2013) 0.88
Chemotrap-1: an engineered soluble receptor that blocks chemokine-induced migration of metastatic cancer cells in vivo. Cancer Res (2010) 0.87
Inhibitors of the CDC25 phosphatases. Prog Cell Cycle Res (2003) 0.87
A screen for deubiquitinating enzymes involved in the G₂/M checkpoint identifies USP50 as a regulator of HSP90-dependent Wee1 stability. Cell Cycle (2010) 0.87
CD8+ T-cell-mediated killing of donor dendritic cells prevents alloreactive T helper type-2 responses in vivo. Blood (2006) 0.87
Unscheduled expression of CDC25B in S-phase leads to replicative stress and DNA damage. Mol Cancer (2010) 0.87
Pathological score for the evaluation of allograft rejection in human hand (composite tissue) allotransplantation. Eur J Dermatol (2005) 0.86
Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. Oncotarget (2011) 0.86
The CDC25B phosphatase shortens the G2 phase of neural progenitors and promotes efficient neuron production. Development (2012) 0.86
Prognostic factors of paraneoplastic pemphigus. Arch Dermatol (2012) 0.85
Nuclear localization of CDC25B1 and serine 146 integrity are required for induction of mitosis. J Biol Chem (2002) 0.85
Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation. Cell Cycle (2009) 0.85
Molecular cloning of SLC26A7, a novel member of the SLC26 sulfate/anion transporter family, from high endothelial venules and kidney. Genomics (2002) 0.84
Synthesis and biological evaluation of novel heterocyclic quinones as inhibitors of the dual specificity protein phosphatase CDC25C. Bioorg Med Chem Lett (2005) 0.84
Asymmetric localization of the CDC25B phosphatase to the mother centrosome during interphase. Cell Cycle (2007) 0.84
Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia. Blood (2010) 0.83
A novel synthetic inhibitor of CDC25 phosphatases: BN82002. Cancer Res (2004) 0.83
Protein kinase Czeta mediated Raf-1/extracellular-regulated kinase activation by daunorubicin. Blood (2002) 0.83
Mitotic phosphorylation of Cdc25B Ser321 disrupts 14-3-3 binding to the high affinity Ser323 site. J Biol Chem (2010) 0.83
Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia. Eur J Pharmacol (2008) 0.83
CDC25B overexpression stabilises centrin 2 and promotes the formation of excess centriolar foci. PLoS One (2013) 0.83
Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly. Mol Cancer Ther (2007) 0.82
Pre-eminence and persistence of immature natural killer cells in acute myeloid leukemia patients in first complete remission. Am J Hematol (2010) 0.82
NanoLC-MS/MS analysis provides new insights into the phosphorylation pattern of Cdc25B in vivo: full overlap with sites of phosphorylation by Chk1 and Cdk1/cycB kinases in vitro. J Proteome Res (2008) 0.82
Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features. Cell Cycle (2008) 0.81
Skin cancers after liver transplantation: retrospective single-center study on 371 recipients. Transplantation (2014) 0.81
Phosphorylation of CDC25C at S263 controls its intracellular localisation. FEBS Lett (2007) 0.80
PKB/Akt phosphorylates the CDC25B phosphatase and regulates its intracellular localisation. Biol Cell (2003) 0.80